Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Renal Dialysis | 23 | 2022 | 355 | 5.990 |
Why?
|
Arteriovenous Shunt, Surgical | 12 | 2019 | 71 | 4.100 |
Why?
|
Kidney Failure, Chronic | 14 | 2022 | 509 | 3.800 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2022 | 350 | 1.910 |
Why?
|
Kidney Transplantation | 5 | 2022 | 849 | 1.760 |
Why?
|
Central Venous Catheters | 3 | 2016 | 23 | 1.650 |
Why?
|
Catheterization, Peripheral | 4 | 2017 | 58 | 1.630 |
Why?
|
Polycystic Kidney, Autosomal Dominant | 2 | 2022 | 136 | 1.510 |
Why?
|
Blood Vessel Prosthesis Implantation | 3 | 2019 | 208 | 1.140 |
Why?
|
Neuromuscular Junction | 3 | 2015 | 80 | 1.130 |
Why?
|
Drosophila | 5 | 2015 | 498 | 1.050 |
Why?
|
Catheterization, Central Venous | 2 | 2017 | 116 | 1.030 |
Why?
|
Graft Rejection | 2 | 2021 | 1065 | 0.980 |
Why?
|
Drosophila Proteins | 7 | 2015 | 488 | 0.880 |
Why?
|
Peritoneal Dialysis | 2 | 2020 | 32 | 0.870 |
Why?
|
Cystatin C | 1 | 2022 | 31 | 0.860 |
Why?
|
Immunosuppressive Agents | 3 | 2019 | 977 | 0.850 |
Why?
|
Polycystic Kidney Diseases | 1 | 2021 | 21 | 0.840 |
Why?
|
Graft Survival | 3 | 2021 | 884 | 0.760 |
Why?
|
Aged | 22 | 2022 | 18415 | 0.730 |
Why?
|
Biological Variation, Individual | 1 | 2019 | 6 | 0.720 |
Why?
|
Transplant Recipients | 1 | 2021 | 122 | 0.720 |
Why?
|
Presynaptic Terminals | 2 | 2015 | 40 | 0.710 |
Why?
|
Transitional Care | 1 | 2019 | 18 | 0.700 |
Why?
|
Renal Replacement Therapy | 1 | 2019 | 30 | 0.690 |
Why?
|
Middle Aged | 26 | 2022 | 25028 | 0.680 |
Why?
|
Male | 32 | 2022 | 40965 | 0.680 |
Why?
|
Drug Monitoring | 1 | 2019 | 118 | 0.670 |
Why?
|
Female | 32 | 2022 | 44532 | 0.660 |
Why?
|
Tacrolimus | 2 | 2019 | 373 | 0.660 |
Why?
|
Patient Transfer | 1 | 2019 | 91 | 0.650 |
Why?
|
Inpatients | 2 | 2015 | 297 | 0.640 |
Why?
|
Graft Occlusion, Vascular | 2 | 2009 | 99 | 0.640 |
Why?
|
Body Mass Index | 1 | 2021 | 770 | 0.610 |
Why?
|
Hemodialysis Solutions | 1 | 2017 | 2 | 0.600 |
Why?
|
Healthcare Disparities | 2 | 2022 | 371 | 0.580 |
Why?
|
Treatment Outcome | 13 | 2021 | 7993 | 0.580 |
Why?
|
Vascular Grafting | 1 | 2016 | 15 | 0.570 |
Why?
|
Upper Extremity | 2 | 2015 | 52 | 0.560 |
Why?
|
Mycophenolic Acid | 2 | 2013 | 87 | 0.530 |
Why?
|
Anti-Glomerular Basement Membrane Disease | 2 | 2013 | 4 | 0.520 |
Why?
|
Humans | 43 | 2022 | 86643 | 0.520 |
Why?
|
Pulmonary Embolism | 2 | 2009 | 222 | 0.510 |
Why?
|
Obesity | 1 | 2021 | 963 | 0.490 |
Why?
|
Plasmapheresis | 1 | 2013 | 26 | 0.470 |
Why?
|
Health Services Accessibility | 1 | 2017 | 394 | 0.460 |
Why?
|
Catheters, Indwelling | 3 | 2008 | 110 | 0.450 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 469 | 0.440 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 827 | 0.430 |
Why?
|
Aged, 80 and over | 9 | 2019 | 6509 | 0.420 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 806 | 0.420 |
Why?
|
Adult | 17 | 2022 | 25648 | 0.410 |
Why?
|
United States | 6 | 2022 | 6672 | 0.410 |
Why?
|
Hospitals, Urban | 2 | 2015 | 54 | 0.400 |
Why?
|
Neuronal Plasticity | 1 | 2013 | 187 | 0.380 |
Why?
|
Physicians, Primary Care | 1 | 2011 | 104 | 0.370 |
Why?
|
Retrospective Studies | 9 | 2022 | 8489 | 0.360 |
Why?
|
Immunoglobulins | 2 | 2015 | 148 | 0.350 |
Why?
|
Practice Patterns, Physicians' | 1 | 2015 | 582 | 0.350 |
Why?
|
Acute Kidney Injury | 4 | 2008 | 295 | 0.350 |
Why?
|
Synapses | 2 | 2015 | 265 | 0.330 |
Why?
|
Lower Extremity | 1 | 2009 | 84 | 0.320 |
Why?
|
Fumarates | 1 | 2008 | 26 | 0.320 |
Why?
|
Spironolactone | 2 | 2009 | 23 | 0.320 |
Why?
|
Amides | 1 | 2008 | 60 | 0.320 |
Why?
|
Thromboembolism | 1 | 2009 | 119 | 0.320 |
Why?
|
Renal Insufficiency | 1 | 2008 | 114 | 0.310 |
Why?
|
Thrombectomy | 1 | 2009 | 158 | 0.300 |
Why?
|
Follow-Up Studies | 3 | 2019 | 3640 | 0.300 |
Why?
|
Anticoagulants | 3 | 2009 | 408 | 0.300 |
Why?
|
Paracentesis | 1 | 2006 | 8 | 0.290 |
Why?
|
Embolism, Cholesterol | 1 | 2006 | 2 | 0.290 |
Why?
|
Tissue Plasminogen Activator | 1 | 2008 | 162 | 0.290 |
Why?
|
Hemodialysis Units, Hospital | 1 | 2006 | 4 | 0.280 |
Why?
|
Odds Ratio | 2 | 2020 | 678 | 0.280 |
Why?
|
Fibrinolytic Agents | 1 | 2008 | 202 | 0.280 |
Why?
|
Ulnar Artery | 1 | 2006 | 5 | 0.280 |
Why?
|
Risk Assessment | 3 | 2019 | 2261 | 0.280 |
Why?
|
Collateral Circulation | 1 | 2006 | 35 | 0.270 |
Why?
|
Venous Thrombosis | 1 | 2009 | 243 | 0.270 |
Why?
|
Risk Factors | 4 | 2019 | 5417 | 0.270 |
Why?
|
Hypertension | 2 | 2020 | 1141 | 0.270 |
Why?
|
Aortic Diseases | 1 | 2006 | 100 | 0.270 |
Why?
|
Pennsylvania | 3 | 2015 | 75 | 0.260 |
Why?
|
Creatinine | 2 | 2022 | 338 | 0.260 |
Why?
|
Thrombosis | 1 | 2008 | 296 | 0.260 |
Why?
|
Protein Interaction Maps | 2 | 2015 | 48 | 0.260 |
Why?
|
Time Factors | 4 | 2019 | 5210 | 0.260 |
Why?
|
Arterial Occlusive Diseases | 1 | 2006 | 107 | 0.260 |
Why?
|
Heparin | 1 | 2005 | 175 | 0.250 |
Why?
|
Vascular Patency | 2 | 2019 | 126 | 0.250 |
Why?
|
Neoplasms | 1 | 2020 | 2898 | 0.250 |
Why?
|
Hemorrhage | 2 | 2008 | 268 | 0.250 |
Why?
|
Databases, Factual | 2 | 2019 | 814 | 0.250 |
Why?
|
Ascites | 1 | 2004 | 55 | 0.250 |
Why?
|
Bone Morphogenetic Proteins | 2 | 2015 | 126 | 0.230 |
Why?
|
Antihypertensive Agents | 1 | 2008 | 521 | 0.230 |
Why?
|
Hyperkalemia | 1 | 2003 | 43 | 0.230 |
Why?
|
Mineralocorticoid Receptor Antagonists | 1 | 2003 | 59 | 0.230 |
Why?
|
Fibronectins | 1 | 2013 | 93 | 0.220 |
Why?
|
Potassium Channels | 1 | 2005 | 340 | 0.220 |
Why?
|
Equipment Design | 3 | 2015 | 406 | 0.210 |
Why?
|
Cohort Studies | 2 | 2021 | 2767 | 0.210 |
Why?
|
Patient Selection | 2 | 2008 | 685 | 0.210 |
Why?
|
Outpatients | 1 | 2022 | 94 | 0.210 |
Why?
|
Vitamin D Deficiency | 1 | 2022 | 103 | 0.200 |
Why?
|
Receptors, Cell Surface | 3 | 2013 | 286 | 0.200 |
Why?
|
Semaphorins | 1 | 2010 | 17 | 0.190 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2010 | 21 | 0.190 |
Why?
|
Glomerular Filtration Rate | 1 | 2022 | 384 | 0.190 |
Why?
|
Larva | 3 | 2015 | 118 | 0.190 |
Why?
|
Potassium | 2 | 2017 | 281 | 0.190 |
Why?
|
Calcium | 3 | 2022 | 1156 | 0.180 |
Why?
|
Peripheral Vascular Diseases | 1 | 2020 | 62 | 0.180 |
Why?
|
Datasets as Topic | 1 | 2019 | 71 | 0.180 |
Why?
|
Angioplasty | 1 | 2019 | 70 | 0.170 |
Why?
|
Arteriovenous Fistula | 1 | 2019 | 52 | 0.170 |
Why?
|
Postoperative Complications | 2 | 2006 | 2207 | 0.170 |
Why?
|
Drosophila melanogaster | 1 | 2013 | 599 | 0.160 |
Why?
|
Prevalence | 2 | 2020 | 1239 | 0.160 |
Why?
|
Polymyositis | 1 | 2018 | 6 | 0.160 |
Why?
|
Dermatomyositis | 1 | 2018 | 17 | 0.160 |
Why?
|
Proteins | 1 | 2013 | 777 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 2 | 2009 | 3362 | 0.150 |
Why?
|
Lung Diseases | 1 | 2020 | 263 | 0.150 |
Why?
|
Hypertrophy, Left Ventricular | 2 | 2009 | 73 | 0.150 |
Why?
|
Bicarbonates | 1 | 2017 | 60 | 0.150 |
Why?
|
Appendicitis | 1 | 2017 | 62 | 0.150 |
Why?
|
Autoantibodies | 1 | 2018 | 267 | 0.140 |
Why?
|
Animals | 9 | 2015 | 26582 | 0.140 |
Why?
|
Magnesium | 1 | 2017 | 177 | 0.140 |
Why?
|
Chronic Disease | 1 | 2020 | 971 | 0.140 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 364 | 0.140 |
Why?
|
Gene Expression Regulation, Developmental | 3 | 2013 | 623 | 0.140 |
Why?
|
Comorbidity | 1 | 2020 | 943 | 0.140 |
Why?
|
Renin | 2 | 2008 | 79 | 0.140 |
Why?
|
Biomarkers | 1 | 2022 | 1718 | 0.140 |
Why?
|
Needs Assessment | 1 | 2017 | 154 | 0.130 |
Why?
|
Eukaryotic Initiation Factor-4E | 1 | 2015 | 16 | 0.130 |
Why?
|
Sodium | 1 | 2017 | 341 | 0.130 |
Why?
|
Catheterization | 2 | 2007 | 232 | 0.130 |
Why?
|
Second Messenger Systems | 1 | 2015 | 41 | 0.130 |
Why?
|
Acyltransferases | 1 | 2015 | 41 | 0.130 |
Why?
|
Monitoring, Physiologic | 1 | 2017 | 268 | 0.130 |
Why?
|
Vesicular Transport Proteins | 1 | 2015 | 63 | 0.130 |
Why?
|
Excitatory Postsynaptic Potentials | 1 | 2015 | 87 | 0.130 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 238 | 0.130 |
Why?
|
Proportional Hazards Models | 1 | 2017 | 859 | 0.120 |
Why?
|
Lung Diseases, Interstitial | 1 | 2018 | 235 | 0.120 |
Why?
|
Hospitals, Teaching | 1 | 2015 | 115 | 0.120 |
Why?
|
Health Care Surveys | 1 | 2015 | 278 | 0.120 |
Why?
|
Schizophrenia | 1 | 2017 | 464 | 0.120 |
Why?
|
Blood Flow Velocity | 2 | 2019 | 197 | 0.120 |
Why?
|
Protein Transport | 1 | 2015 | 411 | 0.120 |
Why?
|
HTLV-I Infections | 1 | 2013 | 7 | 0.120 |
Why?
|
Strongyloidiasis | 1 | 2013 | 5 | 0.120 |
Why?
|
Meningitis, Bacterial | 1 | 2013 | 13 | 0.120 |
Why?
|
Sex Factors | 1 | 2017 | 1054 | 0.120 |
Why?
|
Practice Guidelines as Topic | 2 | 2015 | 1036 | 0.120 |
Why?
|
Quality Indicators, Health Care | 1 | 2015 | 144 | 0.120 |
Why?
|
Program Evaluation | 1 | 2015 | 297 | 0.120 |
Why?
|
Organs at Risk | 1 | 2013 | 41 | 0.120 |
Why?
|
Bone Morphogenetic Protein Receptors | 1 | 2013 | 5 | 0.110 |
Why?
|
Medicare | 1 | 2017 | 410 | 0.110 |
Why?
|
Fertility Preservation | 1 | 2013 | 18 | 0.110 |
Why?
|
Vitiligo | 1 | 2013 | 15 | 0.110 |
Why?
|
Logistic Models | 1 | 2017 | 1186 | 0.110 |
Why?
|
Guideline Adherence | 1 | 2015 | 223 | 0.110 |
Why?
|
Graves Disease | 1 | 2013 | 36 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 1961 | 0.110 |
Why?
|
Animals, Genetically Modified | 2 | 2010 | 181 | 0.110 |
Why?
|
Prognosis | 2 | 2018 | 3679 | 0.110 |
Why?
|
Survival Rate | 1 | 2016 | 1863 | 0.110 |
Why?
|
Medical Tourism | 1 | 2011 | 5 | 0.100 |
Why?
|
Hand | 1 | 2013 | 130 | 0.100 |
Why?
|
Signal Transduction | 2 | 2013 | 3241 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 263 | 0.100 |
Why?
|
Protein Binding | 1 | 2015 | 1456 | 0.100 |
Why?
|
Leishmania | 1 | 2001 | 7 | 0.100 |
Why?
|
Cadaver | 1 | 2011 | 185 | 0.100 |
Why?
|
Cyclosporine | 2 | 2007 | 234 | 0.100 |
Why?
|
RNA Editing | 1 | 2001 | 34 | 0.100 |
Why?
|
Stroke | 1 | 2020 | 965 | 0.090 |
Why?
|
Postoperative Care | 1 | 2011 | 221 | 0.090 |
Why?
|
Adolescent | 3 | 2018 | 8981 | 0.090 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 1621 | 0.090 |
Why?
|
Sequence Alignment | 2 | 2015 | 351 | 0.090 |
Why?
|
Membrane Proteins | 1 | 2015 | 1196 | 0.090 |
Why?
|
Brachial Artery | 1 | 2009 | 36 | 0.080 |
Why?
|
Equipment Contamination | 1 | 2008 | 22 | 0.080 |
Why?
|
Veins | 1 | 2009 | 94 | 0.080 |
Why?
|
Tissue Donors | 1 | 2011 | 463 | 0.080 |
Why?
|
Tomography, Spiral Computed | 1 | 2009 | 76 | 0.080 |
Why?
|
Biofilms | 1 | 2008 | 42 | 0.080 |
Why?
|
Biological Availability | 1 | 2008 | 92 | 0.080 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2008 | 104 | 0.080 |
Why?
|
Prednisolone | 1 | 2007 | 41 | 0.080 |
Why?
|
Tissue and Organ Procurement | 1 | 2011 | 311 | 0.080 |
Why?
|
Sex Distribution | 1 | 2007 | 173 | 0.070 |
Why?
|
Neurons | 1 | 2015 | 1546 | 0.070 |
Why?
|
Equipment Safety | 1 | 2006 | 31 | 0.070 |
Why?
|
Women's Health | 1 | 2007 | 100 | 0.070 |
Why?
|
Hemoptysis | 1 | 2006 | 24 | 0.070 |
Why?
|
Administration, Oral | 1 | 2008 | 684 | 0.070 |
Why?
|
Prospective Studies | 2 | 2019 | 4213 | 0.070 |
Why?
|
Shock | 1 | 2006 | 42 | 0.070 |
Why?
|
Amino Acid Sequence | 2 | 2015 | 2062 | 0.070 |
Why?
|
Albumins | 1 | 2006 | 133 | 0.070 |
Why?
|
Demography | 1 | 2006 | 177 | 0.070 |
Why?
|
Radial Artery | 1 | 2006 | 33 | 0.070 |
Why?
|
Stomach | 1 | 2006 | 108 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2008 | 894 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2006 | 293 | 0.070 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2005 | 23 | 0.070 |
Why?
|
Organizational Culture | 1 | 2005 | 33 | 0.070 |
Why?
|
Critical Care | 1 | 2008 | 370 | 0.070 |
Why?
|
Personnel, Hospital | 1 | 2005 | 30 | 0.070 |
Why?
|
Spleen | 1 | 2006 | 430 | 0.060 |
Why?
|
Japan | 2 | 2017 | 307 | 0.060 |
Why?
|
Kidney Calculi | 1 | 2008 | 339 | 0.060 |
Why?
|
Shaker Superfamily of Potassium Channels | 1 | 2005 | 49 | 0.060 |
Why?
|
Platelet Count | 1 | 2004 | 92 | 0.060 |
Why?
|
Nephrology | 1 | 2005 | 45 | 0.060 |
Why?
|
Kidney | 2 | 2006 | 1241 | 0.060 |
Why?
|
Respiratory Insufficiency | 1 | 2006 | 150 | 0.060 |
Why?
|
Acute Disease | 1 | 2006 | 826 | 0.060 |
Why?
|
Serum Albumin | 1 | 2004 | 130 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2008 | 865 | 0.060 |
Why?
|
Radiography | 1 | 2006 | 813 | 0.060 |
Why?
|
Aldosterone | 1 | 2003 | 65 | 0.060 |
Why?
|
Nephrectomy | 1 | 2005 | 294 | 0.060 |
Why?
|
Endocarditis | 1 | 2003 | 18 | 0.060 |
Why?
|
Brain | 1 | 2013 | 2216 | 0.050 |
Why?
|
Ligands | 1 | 2013 | 433 | 0.050 |
Why?
|
Behavior, Animal | 1 | 2005 | 373 | 0.050 |
Why?
|
Vitamins | 1 | 2022 | 81 | 0.050 |
Why?
|
Protein Structure, Tertiary | 1 | 2013 | 736 | 0.050 |
Why?
|
Parathyroid Hormone | 1 | 2022 | 218 | 0.050 |
Why?
|
Liver | 1 | 2006 | 1230 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2010 | 29 | 0.050 |
Why?
|
Calcium Channels, N-Type | 1 | 2010 | 17 | 0.050 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2002 | 164 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2005 | 508 | 0.050 |
Why?
|
Muscles | 1 | 2010 | 194 | 0.050 |
Why?
|
Lung | 1 | 2006 | 1170 | 0.050 |
Why?
|
Vitamin D | 1 | 2022 | 261 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2005 | 636 | 0.050 |
Why?
|
Electric Stimulation | 1 | 2010 | 347 | 0.040 |
Why?
|
Embryo, Nonmammalian | 1 | 2010 | 193 | 0.040 |
Why?
|
Kidneys, Artificial | 1 | 2019 | 4 | 0.040 |
Why?
|
Motor Neurons | 1 | 2010 | 162 | 0.040 |
Why?
|
Blood Pressure | 1 | 2004 | 1143 | 0.040 |
Why?
|
Brachiocephalic Veins | 1 | 2019 | 33 | 0.040 |
Why?
|
Ultrasonography, Doppler | 1 | 2019 | 80 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 3030 | 0.040 |
Why?
|
Phenotype | 1 | 2005 | 2378 | 0.040 |
Why?
|
Aspirin | 1 | 2019 | 156 | 0.040 |
Why?
|
Interferon-Induced Helicase, IFIH1 | 1 | 2018 | 10 | 0.040 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2002 | 383 | 0.040 |
Why?
|
Amino Acyl-tRNA Synthetases | 1 | 2018 | 14 | 0.040 |
Why?
|
Somatosensory Disorders | 1 | 2017 | 3 | 0.040 |
Why?
|
Phylogeny | 1 | 2013 | 1137 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2018 | 129 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2010 | 503 | 0.040 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 243 | 0.040 |
Why?
|
Action Potentials | 1 | 2010 | 573 | 0.040 |
Why?
|
Genetic Testing | 1 | 2010 | 535 | 0.040 |
Why?
|
Young Adult | 2 | 2018 | 5976 | 0.030 |
Why?
|
Multigene Family | 1 | 2015 | 202 | 0.030 |
Why?
|
Streptococcus bovis | 1 | 2013 | 2 | 0.030 |
Why?
|
Coinfection | 1 | 2013 | 58 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2017 | 1805 | 0.030 |
Why?
|
Age Factors | 1 | 2017 | 1851 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 2013 | 220 | 0.030 |
Why?
|
Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 1991 | 8 | 0.030 |
Why?
|
RNA, Protozoan | 1 | 2001 | 5 | 0.030 |
Why?
|
Kidney Tubules | 1 | 1991 | 94 | 0.020 |
Why?
|
Models, Molecular | 1 | 2015 | 1286 | 0.020 |
Why?
|
Uridine | 1 | 2001 | 56 | 0.020 |
Why?
|
Protozoan Proteins | 1 | 2001 | 73 | 0.020 |
Why?
|
Gene Deletion | 1 | 2001 | 329 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2001 | 217 | 0.020 |
Why?
|
Mutation | 1 | 2010 | 3968 | 0.020 |
Why?
|
Cell Cycle | 1 | 2001 | 502 | 0.020 |
Why?
|
Dialysis Solutions | 1 | 2008 | 7 | 0.020 |
Why?
|
Convection | 1 | 2008 | 12 | 0.020 |
Why?
|
Hypothermia | 1 | 2008 | 26 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2008 | 121 | 0.020 |
Why?
|
Diffusion | 1 | 2008 | 93 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2001 | 1981 | 0.020 |
Why?
|
Equipment Failure | 1 | 2008 | 119 | 0.020 |
Why?
|
Mitochondria | 1 | 2001 | 535 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 1991 | 1135 | 0.020 |
Why?
|
RNA | 1 | 2001 | 560 | 0.020 |
Why?
|
Critical Illness | 1 | 2008 | 294 | 0.020 |
Why?
|
Hemodynamics | 1 | 2008 | 710 | 0.020 |
Why?
|
Sepsis | 1 | 2008 | 306 | 0.020 |
Why?
|
Rats, Inbred Strains | 1 | 1991 | 312 | 0.010 |
Why?
|
Gene Expression | 1 | 1991 | 1284 | 0.000 |
Why?
|
Rats | 1 | 1991 | 3990 | 0.000 |
Why?
|
Models, Biological | 1 | 1991 | 1749 | 0.000 |
Why?
|